Quick Answer
Altimmune, Inc. reported Long-Term Debt of $34.29 million for fiscal year 2025.
Altimmune, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $34.29M | +4595.1% |
| 2013 | $730.3K | -57.1% |
| 2012 | $1.70M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.45M | — | +0.8% |
| June 30, 2025 | $14.33M | — | +2328.4% |
| September 30, 2017 | $590.2K | — | +3.4% |
| June 30, 2017 | $570.5K | — | +8.5% |
| December 31, 2016 | $526.0K | — | +119.4% |
| June 30, 2014 | $239.7K | -80.3% | -50.6% |
| March 31, 2014 | $485.4K | -66.8% | -33.5% |
| December 31, 2013 | $730.3K | -57.1% | -25.1% |
- Altimmune, Inc. showed an increase of +4595.1% in Long-Term Debt compared to the prior fiscal year.
- Over the 2012–2025 period, Altimmune, Inc.’s long-term debt has grown by 1912.0% (from $1.70 million to $34.29 million).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: